CL2011003050A1 - Compuestos derivados de 17beta-alquil-17alfa-oxi-estratrienos sustituidos; compuestos intermediarios derivados de oxitrienos; composicion farmaceutica; utiles en el tratamiento de trastornos dependientes del estrogeno. - Google Patents
Compuestos derivados de 17beta-alquil-17alfa-oxi-estratrienos sustituidos; compuestos intermediarios derivados de oxitrienos; composicion farmaceutica; utiles en el tratamiento de trastornos dependientes del estrogeno.Info
- Publication number
- CL2011003050A1 CL2011003050A1 CL2011003050A CL2011003050A CL2011003050A1 CL 2011003050 A1 CL2011003050 A1 CL 2011003050A1 CL 2011003050 A CL2011003050 A CL 2011003050A CL 2011003050 A CL2011003050 A CL 2011003050A CL 2011003050 A1 CL2011003050 A1 CL 2011003050A1
- Authority
- CL
- Chile
- Prior art keywords
- 17alpha
- 17beta
- oxy
- alkyl
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Compuestos derivados de 17beta-alquil-17alfa-oxi-estratrienos; compuestos intermediarios; composición farmacéutica; y su uso para tratar trastornos dependientes de estrógenos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09075249A EP2258375A1 (de) | 2009-06-04 | 2009-06-04 | 17B-alkyl-17alpha-oxy-estratriene |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011003050A1 true CL2011003050A1 (es) | 2012-06-15 |
Family
ID=41460961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011003050A CL2011003050A1 (es) | 2009-06-04 | 2011-12-02 | Compuestos derivados de 17beta-alquil-17alfa-oxi-estratrienos sustituidos; compuestos intermediarios derivados de oxitrienos; composicion farmaceutica; utiles en el tratamiento de trastornos dependientes del estrogeno. |
Country Status (27)
Country | Link |
---|---|
US (1) | US20120157421A1 (es) |
EP (2) | EP2258375A1 (es) |
JP (1) | JP2012528808A (es) |
KR (1) | KR20120042827A (es) |
CN (1) | CN102802634A (es) |
AR (1) | AR076980A1 (es) |
AU (1) | AU2010256035A1 (es) |
BR (1) | BRPI1013017A2 (es) |
CA (1) | CA2764249A1 (es) |
CL (1) | CL2011003050A1 (es) |
CO (1) | CO6470855A2 (es) |
CR (1) | CR20110647A (es) |
CU (1) | CU20110224A7 (es) |
DO (1) | DOP2011000374A (es) |
EA (1) | EA201101703A1 (es) |
EC (1) | ECSP11011501A (es) |
IL (1) | IL216524A0 (es) |
MA (1) | MA33329B1 (es) |
MX (1) | MX2011012878A (es) |
NZ (1) | NZ596824A (es) |
PE (1) | PE20120318A1 (es) |
SG (1) | SG176630A1 (es) |
TN (1) | TN2011000617A1 (es) |
TW (1) | TW201103547A (es) |
UY (1) | UY32688A (es) |
WO (1) | WO2010139411A2 (es) |
ZA (1) | ZA201200036B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116535454A (zh) * | 2023-04-28 | 2023-08-04 | 香港中文大学(深圳) | 氟维司群类化合物及其制备方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
EP0310542B1 (de) | 1987-10-01 | 1994-06-08 | Schering Aktiengesellschaft | Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren |
GB8813353D0 (en) | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
DE19510862A1 (de) | 1995-03-16 | 1996-09-19 | Schering Ag | Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle |
DE19622457A1 (de) | 1996-05-24 | 1997-11-27 | Schering Ag | 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
PE20000129A1 (es) | 1997-12-23 | 2000-03-11 | Schering Ag | 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa |
DE10019171A1 (de) | 2000-04-07 | 2001-10-18 | Schering Ag | Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe |
DE10159217A1 (de) * | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
-
2009
- 2009-06-04 EP EP09075249A patent/EP2258375A1/de not_active Withdrawn
-
2010
- 2010-05-26 CA CA2764249A patent/CA2764249A1/en not_active Abandoned
- 2010-05-26 WO PCT/EP2010/003204 patent/WO2010139411A2/de active Application Filing
- 2010-05-26 MA MA34401A patent/MA33329B1/fr unknown
- 2010-05-26 AU AU2010256035A patent/AU2010256035A1/en not_active Abandoned
- 2010-05-26 BR BRPI1013017A patent/BRPI1013017A2/pt not_active Application Discontinuation
- 2010-05-26 EP EP10722316A patent/EP2437746A2/de not_active Withdrawn
- 2010-05-26 US US13/376,194 patent/US20120157421A1/en not_active Abandoned
- 2010-05-26 JP JP2012513491A patent/JP2012528808A/ja not_active Withdrawn
- 2010-05-26 SG SG2011089034A patent/SG176630A1/en unknown
- 2010-05-26 EA EA201101703A patent/EA201101703A1/ru unknown
- 2010-05-26 CN CN2010800342808A patent/CN102802634A/zh active Pending
- 2010-05-26 MX MX2011012878A patent/MX2011012878A/es unknown
- 2010-05-26 NZ NZ596824A patent/NZ596824A/xx not_active IP Right Cessation
- 2010-05-26 KR KR1020127000101A patent/KR20120042827A/ko not_active Application Discontinuation
- 2010-05-26 PE PE2011002048A patent/PE20120318A1/es not_active Application Discontinuation
- 2010-06-03 UY UY0001032688A patent/UY32688A/es not_active Application Discontinuation
- 2010-06-04 AR ARP100101978A patent/AR076980A1/es unknown
- 2010-06-04 TW TW099118274A patent/TW201103547A/zh unknown
-
2011
- 2011-11-22 IL IL216524A patent/IL216524A0/en unknown
- 2011-12-02 TN TNP2011000617A patent/TN2011000617A1/en unknown
- 2011-12-02 CL CL2011003050A patent/CL2011003050A1/es unknown
- 2011-12-02 CO CO11166108A patent/CO6470855A2/es not_active Application Discontinuation
- 2011-12-02 CU CU20110224A patent/CU20110224A7/es unknown
- 2011-12-02 EC EC2011011501A patent/ECSP11011501A/es unknown
- 2011-12-02 CR CR20110647A patent/CR20110647A/es unknown
- 2011-12-02 DO DO2011000374A patent/DOP2011000374A/es unknown
-
2012
- 2012-01-03 ZA ZA2012/00036A patent/ZA201200036B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20120042827A (ko) | 2012-05-03 |
EP2437746A2 (de) | 2012-04-11 |
CN102802634A (zh) | 2012-11-28 |
AU2010256035A1 (en) | 2011-12-22 |
NZ596824A (en) | 2013-07-26 |
WO2010139411A2 (de) | 2010-12-09 |
ZA201200036B (en) | 2013-06-26 |
DOP2011000374A (es) | 2012-01-15 |
TN2011000617A1 (en) | 2013-05-24 |
IL216524A0 (en) | 2012-02-29 |
BRPI1013017A2 (pt) | 2016-03-29 |
JP2012528808A (ja) | 2012-11-15 |
ECSP11011501A (es) | 2012-01-31 |
CU20110224A7 (es) | 2012-04-15 |
MX2011012878A (es) | 2012-01-12 |
UY32688A (es) | 2010-12-31 |
AR076980A1 (es) | 2011-07-20 |
WO2010139411A3 (de) | 2011-03-10 |
CO6470855A2 (es) | 2012-06-29 |
SG176630A1 (en) | 2012-01-30 |
CR20110647A (es) | 2012-02-16 |
EP2258375A1 (de) | 2010-12-08 |
MA33329B1 (fr) | 2012-06-01 |
PE20120318A1 (es) | 2012-03-24 |
EA201101703A1 (ru) | 2012-06-29 |
CA2764249A1 (en) | 2010-12-09 |
US20120157421A1 (en) | 2012-06-21 |
TW201103547A (en) | 2011-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
CL2011001299A1 (es) | Compuestos derivados de benzotiazoles; composicion farmaceutica; y su uso como inhibidores de raf para el tratamiento o profilaxis del cancer. | |
CL2012001405A1 (es) | Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer. | |
TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
CO6440531A2 (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
PE20150631A1 (es) | Formas cristalinas de un modulador del receptor androgenico | |
CL2011002787A1 (es) | Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica. | |
CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
CL2011002818A1 (es) | Composicion de leche para el crecimiento que comprende microorganismos probioticos; uso de dicha composicion para preparar medicamento util para prevenir o tratar trastornos inflamatorios. | |
EA201300730A1 (ru) | Производные индазолилтриазола | |
CL2009000650A1 (es) | Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras | |
CL2011002877A1 (es) | Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer. | |
CL2011003229A1 (es) | Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer. | |
GT201400111A (es) | Triazolopiridinas sustituidas | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
ECSP13012573A (es) | 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3 | |
CL2010001474A1 (es) | Compuestos derivados de tiofeno o tiazol sustituidos, inhibidores de pi3k; composicion farmaceutica; utiles en el tratamiento del cancer, inflamacion y en el tratamiento de trastornos cardiovasculares. | |
EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
CL2013000455A1 (es) | Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer. | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
UY32937A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
CL2012003681A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes. | |
CL2009000119A1 (es) | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. |